Recent advances in the discovery and development of anti-influenza drugs

Expert Opinion on Therapeutic Patents

Volumn 12, Issue 6, 2002, Pages 845-861

  Wang, Gary T ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Amantadine; Anti influenza therapy; Haemagglutinin; Influenza virus fusion; Neuraminidase; Oseltamivir; Zanamivir

Indexed keywords

2 DEOXY 2,3 DIDEHYDRO N ACETYL NEURAMINIC ACID; 4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; A 192558; ABT 667; ABT 675; ANTIVIRUS AGENT; GLYCOPROTEIN; INFLUENZA VACCINE; OSELTAMIVIR; PERAMIVIR; RIMANTADINE; SIALIDASE INHIBITOR; UNCLASSIFIED DRUG; VIRUS ENZYME; VIRUS SIALIDASE; ZANAMIVIR; ZANMIVIR DERIVATIVE;

ANTIVIRAL ACTIVITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG FORMULATION; DRUG SYNTHESIS; DRUG TARGETING; ENZYME INHIBITION; FOOD AND DRUG ADMINISTRATION; HUMAN; INFLUENZA; INFLUENZA VIRUS A; INFLUENZA VIRUS B; NONHUMAN; PATENT; REVIEW; UNITED STATES; VIRUS REPLICATION;

EID: 0036078407     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.12.6.845     Document Type: Review

References (79)

1. Researchers seek new weapon against the flu
2. Serious morbidity and mortality associated with influenza epidemics
3. Impact of influenza and respiratory syncytial virus on mortality in England and Wales from January 1975 to December 1990
4. Taking aim at a moving target-inhibitors of influenza virus Part 1: Virus adsorption, entry and uncoating
5. Taking aim at a moving target-inhibitors of influenza virus Part 2: Viral replication, packaging and release
6. The action of adamantine amines against influenza A viruses: Inhibition of the M2 ion channel protein
7. Comparative single-dose pharmacokinetics pf amantadine hydrochloride and rimantadine hydrochloride in young and elderly adults
8. Emergence and apparent transmession of rimantadine-resistant influenza A virus in families
9. Influence of amantadine resistance mutations on the pH regulatory function of the M2 protein of influenza A virus
10. New approaches to influenza chemotherapy
11. The neuraminidase of influenza virus
12. Influenza A virus
13. Evidence for a sialosyl cation transition state complex in the reaction of sialidase from influenza virus
14. Characterization of temperature-sensitive influenza virus mutants defective in neuraminidase
15. Structure of the catalytic and antigenic sites in influenza virus neuraminidase
16. Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9 Å resolution
17. The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor
18. The 2.2 Å resolution crystal structure of influenza B neuraminidase and its complex with sialic acid
19. Three-dimensional structure of the complex of 4-guanidino-Neu5Ac2en and influenza virus neuraminidase
20. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: Design, synthesis and structural analysis of carbocyclic sialic acid analogs with potent anti-influenza activity
21. Dihydropyrancarboxamides Related to zanamivir: A new class of inhibitors of influenza virus sialidase. 2. Crystallographic and molecular modeling study of complex of 4-amino-4H-pyran-6-carboxamides and sialidase from A and B
22. BCX-1812 (RWJ-270201): Discovery of a novel, highly potent, orally-active and selective influenza neuraminidase inhibitor through structure-based drug design
23. Design, synthesis and structural analysis of influenza neuraminidase inhibitors containing pyrrolidine cores
24. Rational design of potent sailidase-based inhibitors of influenza virus replication
25. Inhibition of Neuraminidase activity by derivatives of 2-deoxy-2,3Dehydro-N-acetylneuraminic acid
26. Inhibition of influenza virus replication in tissue culture by 2-deoxy-2,3Dehydro-N-trifluoroacetyl-neuraminic acid (FANA): Mechanism of action
27. Inhibition of influenza and parainfluenza virus replication in tissue culture by 2-deoxy-2,3Dehydro-N-trifluoroacetylneuraminic acid (FANA)
28. Approaches and strategies for the treatment of influenza virus infections
29. Neuramininidase inhibitors as anti-influenza virus agents
30. Synthesis and influenza virus sialidase inhibitory activity of the 5-desacetamide analog of 2,3Didehydro-2, 4-dideoxy-4-guanidinyl-N-acetylneuraminic acid (GG167)
31. Synthesis and influenza virus sialidase inhibitory activity of analogues of 4-guanidino-Neu5Ac2en (GG167) with modified 5-substitution
32. Synthesis of 6-, 7- and 8-carbon sugar analogues of potent anti-influenza 2,3didehydro-2,3dideoxy-N-acetyl-neuraminic acid derivatives
33. Inhibition of influenza virus replication in mice by GG167 (4-guanidino-2,4-dideoxy-2,3dehydro-N-acetylneuraminic acid) is consistent with extracellular activity of viral neuraminidase (sialidase)
34. Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza
35. Novel inhibitors of influenza sialidase related to GG167: Synthesis of 4-amino and guanidino-4H-pyran-2-carboxylic acid-6-propylamides: Selective inhibitors of influenza A virus
36. Novel inhibitors of influenza sialidase related to GG167: Structure-activity, crystallographic and molecular dynamic studies with 4H-pyran-2-carboxylic acid 6-carboxamide. Bioorg
37. Dihydropyrancarboxamides related to zanamivir: A new series of inhibitors of influenza virus sialidase. 1. discovery, synthesis, biological 4-amino-4H-pyran-6-carboxamides
38. Sialidase inhibitors related to GG167: Synthesis of analogues via an inverse demand hetero Diels-Alder Reaction
39. Structure-activity relationship studies of novel carbocyclic influenza neuraminidase inhibitors
40. Structure-activity relationship studies of novel carbocyclic influenza neuraminidase inhibitors
41. 3-carba isosteres of a carbocyclic influenza neuraminidase inhibitors, (3R,4R,5S)-4-acetamido-5-amino-3-propoxy-1-cyclohexene-1-carboxylic acid
42. Synthesis and activity of C2-substituted analogs of influenza neuraminidase inhibitor GS4071
43. Identification of GS4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS4071
44. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: Randomized controlled trials for prevention and treatment
45. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza
46. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: A randomized controlled trial
47. Oral oseltamivir in human experimental influenza B infection
48. 3-aza carbocyclic influenza neuraminidase inhibitors: Synthesis and inhibitory activity
49. 3-cyclic amine side chain: Synthesis and inhibitory activity
50. Synthesis and evaluation of 1,4,5,6,-tetrahydropyridazine derivatives as influenza neuraminidase inhibitors
51. Systematic structure-based design and stereoselective synthesis of novel multisubstituted cyclopentane derivatives with anti-influenza activity
52. Cyclopentane neuraminidase inhibitors with potent in vitro anti-influenza virus activities
53. Cyclopentane neuraminidase inhibitors with potent in vitro anti-influenza virus activities
54. Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir
55. Novel α- and β-amino acid inhibitors of influenza virus neuraminidase
56. Synthesis of 2-substituted (±)-(2R, 3R, 5R)-tetrahydrofuran-3,5-dicarboxylic acid derivatives
57. Structure-based inhibitors of influenza virus sialidase. A benzoic acid lead with novel interaction
58. Synthesis and influenza neuraminidase inhibitory activity of aromatic analogues of sialic acid
59. Design and synthesis of benzoic acid derivatives as influenza neuraminidase inhibitors using structure-based drug design
60. Design of benzoic acid inhibitors of influenza neuraminidase containing a cyclic substitution for the N-acetyl grouping
61. Potent inhibition of influenza sialidase by a benzoic acid containing a 2-pyrrolidinone substituent
62. Molecular basis for the resistance of influenza viruses to 4-guanidino-Neu5Ac2en
63. Generation and characterization of an influenza virus neuraminidase variant with decreased sensitivity to the neuraminidase-specific inhibitor 4-guanidino-Neu5Ac2en
64. Generation and characterization of NWS/G70C influenza virus after in vitro passage in 4-guanidino-Neu5Ac2en
65. Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidino-Neu5Ac2en
66. Comparison of the activities of zanamivir, oseltamivir and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants
67. Characterization of an influenza A (H3N2) virus resistant to the cyclopentane neuraminidase inhibitor RWJ-270201
68. Catalytic and framework mutation in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en
69. Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS4071
70. Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir
71. In vitro characterization of A-315675, a highly potent inhibitor of A and B strain influenza virus neuraminidase and influenza replication
72. Novel quinolizidine salicylamide influenza fusion inhibitors
73. An approach to the identification of potent inhibitors of influenza virus fusion using parallel synthesis methodology
74. Anti-influenza virus activities of 2-alkoxyimino-N-(2-isoxazolin-3-ylmethyl)-acetamides
75. Resistance of influenza viruses to neuraminidase inhibitors - A review
76. Generation and characterization of a mutant of influenza A virus selected with the neuraminidase inhibitor RWJ-270201